The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).
 
Todd Michael Bauer
Employment - Sarah Cannon Research Institute; Tennessee Oncology
Consulting or Advisory Role - Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Peleton (Inst); Pfizer (Inst); Principa Biopharma (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst)
 
Mrinal M. Gounder
Honoraria - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; TRACON Pharma
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Speakers' Bureau - Amgen
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics
Other Relationship - Desmoid Tumor Research Foundation
 
Amy M. Weise
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis
 
Prasanna Kumar
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Oleg Zernovak
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo; Merck; Novartis
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Alida Beck
No Relationships to Disclose
 
Jana Doyle
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Pfizer
 
Jeanne Mendell-Harary
Employment - Daiichi Sankyo
 
Jarema Peter Kochan
Employment - Daiichi Sankyo
 
Shuquan Chen
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Patricia LoRusso
Leadership - Agios; Five Prime Therapeutics; Halozyme; Roche/Genentech
Honoraria - Genentech/Roche
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; CytomX Therapeutics; Genentech; Genentech; Genmab; Glenmark; Ignyta; Menarini; Novartis; Omniox; Takeda
Research Funding - Alexion Pharmaceuticals; Boehringer Ingelheim; Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer; Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
William D. Tap
Consulting or Advisory Role - Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; Immune Design; Janssen; Lilly; Loxo; Novartis; Plexxikon; TRACON Pharma
 
Neeta Somaiah
Consulting or Advisory Role - Bayer; Deciphera; Immune Design
Research Funding - MedImmune
 
David Michael Hyman
Consulting or Advisory Role - ArQule; AstraZeneca; Atara Biotherapeutics; Bayer; Boehringer Ingelheim; Chugai Pharma; CytomX Therapeutics; Debiopharm Group; Genentech; Pfizer
Research Funding - AstraZeneca; Loxo; Puma Biotechnology
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Clearlight Diagnostics; DarwinHealth; Genentech; GRAIL; Inflection Biosciences; Pieris Pharmaceuticals; Samsung Bioepis
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; eFFECTOR Therapeutics; Genentech; Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena